A metabolic marker–based diagnostic model for precancerous and malignant endometrial lesions in insulin-resistant PCOS women with sonographically suspected endometrial polyps - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

A Diagnostic Model Utilizing Metabolic Markers for Identifying Precancerous and Malignant Endometrial Lesions in Women with Insulin-Resistant PCOS and Suspected Endometrial Polyps

  • By

  • Ying Yang

  • Ningning Hu

  • Weimin Fan

  • Liwen Zhang

  • He Fei

  • Jun Ye

  • Yang Gao

  • Ju Yang

  • Jiangnan Pei

  • Rujun Chen

  • July 13, 2026

Share

  • 1

    The study involved 185 PCOS-IR patients with ultrasound-detected endometrial polyps, categorized into benign, atypical hyperplasia, and endometrial carcinoma groups.

  • 2

    The endometrial neoplasia group showed significantly higher HOMA-IR, fasting plasma glucose, and fasting insulin compared to the benign group.

  • 3

    The final predictive model included age, HDL-C, free androgen index, and HOMA-IR, achieving moderate discrimination with an AUC of 0.767.

  • 4

    High sensitivity (0.913) and a specificity of 0.500 were observed in the model, indicating its potential for risk stratification.

  • 5

    The model remains hypothesis-generating and requires further external validation before clinical application due to its exploratory nature.

Original Source(s)

A metabolic marker–based diagnostic model for precancerous and malignant endometrial lesions in insulin-resistant PCOS women with sonographically suspected endometrial polyps

  • by Ying Yang, Ningning Hu, Weimin Fan, Liwen Zhang, He Fei, Jun Ye, Yang Gao, Ju Yang, Jiangnan Pei, Rujun Chen

  • July 13, 2026

Related Content

Editorial Expression of Concern: Office microlaparoscopic ovarian drilling (OMLOD) versus conventional laparoscopic ovarian drilling (LOD) for women with polycystic ovary syndrome

Do Sitting Patterns Matter?

Researchers analyzed UK Biobank data to determine whether spending sedentary time in prolonged vs interrupted bouts was associated with subsequent cancer incidence and cancer mortality.

FDA Approves Gedatolisib in Breast Cancer

In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.